Minerva Neurosciences | NERV - Equity Capital And Reserves


Minerva Neurosciences reported $-140.75M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Adma Biologics USD 477.32M 46.13M Dec/2025
ALKERMES USD 1.75B 67.76M Mar/2026
Alterity Therapeutics Limited AUD 36.21M 18.58M Dec/2025
AstraZeneca USD 47.33B 1.33B Mar/2026
BioCryst Pharmaceuticals USD -119.15M 268.74M Dec/2025
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Cipla INR 329.19B 16.3B Sep/2025
Clal Biotechnology ILS 121.41M 4.62M Dec/2023
Compugen USD 102.73M 58.9M Dec/2025
CSL USD 18.66B 2.75B Dec/2025
Eli Lilly USD 31.2B 4.66B Mar/2026
Esperion Therapeutics USD -301.96M 149.4M Dec/2025
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
Grifols EUR 6.21B 133.12M Dec/2025
Halozyme Therapeutics USD 48.81M 455.1M Dec/2025
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
J&J USD 81.19B 358M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Minerva Neurosciences USD -140.75M 106.17M Dec/2025
Neurocrine Biosciences USD 3.41B 154.3M Mar/2026
Novartis USD 38.93B 7.2B Mar/2026
Novavax USD -127.75M 28.92M Dec/2025
Pfizer USD 90.1B 3.63B Mar/2026
Roche Holding CHF 33.8B 758M Dec/2025
Sanofi EUR 72.81B 1.1B Mar/2026
Takeda JPY 7.64T 513.39B Dec/2025
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025